Last reviewed · How we verify

NCT05124951

The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors

Recruiting now Phase 2 Last updated 18 November 2021
What this trial tests

Phase 2 trial testing Whole-ventricle irradiation in Intracranial Germ Cell CNS Tumor, Childhood in 150 participants. Currently enrolling.

Timeline
15 September 2021
Primary endpoint
31 October 2026
31 October 2026

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment150
Start date15 September 2021
Primary completion31 October 2026
Estimated completion31 October 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 3 to 30, any sex, with Intracranial Germ Cell CNS Tumor, Childhood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary endpoint 1. three-year disease-free survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Health-related quality of life measured by PedsQL 4.0 and SF-36 Second endpoint 1. three-year overall survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Adverse effects of chemoradiotherapy measured by NCI CTCAE 5.0

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05124951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing